Locally Advanced Gastroesophageal Junction Adenocarcinoma Clinical Trials

5 recruiting

Locally Advanced Gastroesophageal Junction Adenocarcinoma Trials at a Glance

5 actively recruiting trials for locally advanced gastroesophageal junction adenocarcinoma are listed on ClinicalTrialsFinder across 4 cities in 2 countries. The largest study group is Phase 1 with 3 trials, with the heaviest enrollment activity in Buffalo, Guangzhou, and Houston. Lead sponsors running locally advanced gastroesophageal junction adenocarcinoma studies include Roswell Park Cancer Institute, Mayo Clinic, and National Cancer Institute (NCI).

Browse locally advanced gastroesophageal junction adenocarcinoma trials by phase

Treatments under study

About Locally Advanced Gastroesophageal Junction Adenocarcinoma Clinical Trials

Looking for clinical trials for Locally Advanced Gastroesophageal Junction Adenocarcinoma? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Locally Advanced Gastroesophageal Junction Adenocarcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Locally Advanced Gastroesophageal Junction Adenocarcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 15 of 5 trials

Recruiting
Phase 1

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+10 more
National Cancer Institute (NCI)48 enrolled1 locationNCT06364410
Recruiting
Phase 1Phase 2

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+97 more
Mayo Clinic132 enrolled1 locationNCT05269381
Recruiting
Phase 1

Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer

Locally Advanced Gastroesophageal Junction AdenocarcinomaMetastatic Gastroesophageal Junction AdenocarcinomaStage IV Colorectal Cancer AJCC v8+26 more
Roswell Park Cancer Institute45 enrolled1 locationNCT04511039
Recruiting
Phase 2

Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Locally Advanced Gastroesophageal Junction Adenocarcinoma+8 more
Roswell Park Cancer Institute40 enrolled1 locationNCT05651594
Recruiting
Phase 2

S-1 and Oxaliplatin (SOX) Plus Sintilimab in the Locally Advanced Esophagogastric Junction Adenocarcinoma

Locally Advanced Gastroesophageal Junction AdenocarcinomaChemotherapy Effect
Sixth Affiliated Hospital, Sun Yat-sen University302 enrolled1 locationNCT04989985